Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...
CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.
CRISPR Therapeutics recently reported that rollout of its approved gene therapy Casgevy for sickle cell disease and transfusion‑dependent beta thalassemia has been slower than hoped, contributing to a ...
Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first ...
Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...
Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...
Researchers identified a CRISPR-based genetic mechanism that restrains the virulence of a key gum disease bacterium.
One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand ...
The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...
Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiationSAN FRANCISCO and BERLIN, ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results